Lilly Closes AtaiBeckley Acquisition to Expand Mental Health Pipeline
LLY sits 59% above its 52-week low of $712.05.
Summary
Lilly completed its acquisition of AtaiBeckley, adding therapies for treatment-resistant depression and other mental health conditions. The deal expands Lilly's neuroscience pipeline beyond its dominant diabetes and obesity franchises. No financial terms were disclosed, but the strategic fit is clear given Lilly's recent focus on high-growth therapeutic areas. This follows a period of heavy acquisition spending noted in the Q2 10-Q. The completion removes uncertainty and adds a new platform for future growth.
At the time of this announcement, LLY was trading at $1,131.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.